Home LiteratureArticle Details
PMID: 15701727 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Review

New approaches for preventing and treating chronic graft-versus-host disease.

Blood ·Vol. 105 ·No. 11 ·2005-06-01 ·Pages 4200-6

Lee SJ

Abstract

Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation (HCT) over the last 25 years, chronic graft-versus-host disease (GVHD) remains a substantial problem with little change in the incidence, morbidity, and mortality of this complication. In fact, with increased use of peripheral blood, transplantation of older patients, and less immediate transplantation-related mortality, the prevalence of chronic GVHD may increase. One of the difficulties in combating chronic GVHD is a lack of understanding about the pathophysiology of the syndrome. Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD.

MeSH Terms
Chronic Disease Graft vs Host Disease/prevention & control,therapy Hematopoietic Stem Cell Transplantation/adverse effects Humans Immunotherapy/methods Premedication
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Lee Stephanie J
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. stephanie_lee@dfci.harvard.edu
References (101)
101 references, click to expand
  1. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors.
    Blood. 2005 Jan 15;105(2):548-51 PMID: 15367429
  2. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
    Blood. 2005 Apr 1;105(7):2973-8 PMID: 15613541
  3. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study.
    Blood. 2004 Sep 15;104(6):1898-906 PMID: 15172972
  4. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial.
    Blood. 2001 Dec 15;98(13):3868-70 PMID: 11739201
  5. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients.
    Br J Haematol. 2001 Dec;115(3):630-41 PMID: 11736948
  6. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease.
    Bone Marrow Transplant. 2001 Dec;28(11):1047-51 PMID: 11781615
  7. Topical treatment of sclerodermoid chronic graft vs. host disease.
    Am J Phys Med Rehabil. 2002 Feb;81(2):143-9 PMID: 11807351
  8. A survey of diagnosis, management, and grading of chronic GVHD.
    Biol Blood Marrow Transplant. 2002;8(1):32-9 PMID: 11846354
  9. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
    J Invest Dermatol. 2002 Mar;118(3):461-70 PMID: 11874485
  10. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease.
    Transplantation. 2002 Feb 27;73(4):665-7 PMID: 11889452
  11. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Science. 2002 Mar 15;295(5562):2097-100 PMID: 11896281
  12. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
    Nat Med. 2002 Apr;8(4):410-4 PMID: 11927949
  13. Effects of exogenous interleukin-7 on human thymus function.
    Blood. 2002 Apr 15;99(8):2851-8 PMID: 11929775
  14. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.
    Blood. 2002 May 15;99(10):3493-9 PMID: 11986199
  15. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease.
    Lancet. 2002 Jun 15;359(9323):2078-83 PMID: 12086762
  16. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
    Blood. 2002 Jul 15;100(2):406-14 PMID: 12091329
  17. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.
    Blood. 2002 Jul 15;100(2):415-9 PMID: 12091330
  18. Cytokine dysregulation in chronic graft versus host disease.
    Leuk Lymphoma. 1995 Mar;17(1-2):169-73 PMID: 7773155
  19. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
    J Immunol. 1995 Sep 1;155(5):2396-406 PMID: 7650373
  20. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.
    Biol Blood Marrow Transplant. 2002;8(8):444-52 PMID: 12234170
  21. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis.
    Bone Marrow Transplant. 2002 Oct;30(8):509-15 PMID: 12379890
  22. Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease.
    Transplantation. 2002 Oct 15;74(7):995-1000 PMID: 12394844
  23. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor.
    Blood. 2002 Nov 15;100(10):3825-7 PMID: 12393440
  24. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation.
    Blood. 2002 Dec 1;100(12):3908-18 PMID: 12393699
  25. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice.
    J Immunol. 2003 Jan 1;170(1):588-96 PMID: 12496447
  26. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Biol Blood Marrow Transplant. 2002;8(12):674-82 PMID: 12523580
  27. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease.
    Transplantation. 2003 Jan 27;75(2):221-5 PMID: 12548127
  28. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Biol Blood Marrow Transplant. 2003 Mar;9(3):170-6 PMID: 12652467
  29. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Haematologica. 2003 Mar;88(3):315-23 PMID: 12651271
  30. Regulatory T cells in transplantation tolerance.
    Nat Rev Immunol. 2003 Mar;3(3):199-210 PMID: 12658268
  31. Natural versus adaptive regulatory T cells.
    Nat Rev Immunol. 2003 Mar;3(3):253-7 PMID: 12658273
  32. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation.
    Lancet. 2003 Apr 5;361(9364):1183-5 PMID: 12686042
  33. Chronic graft-versus-host disease.
    Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33 PMID: 12720215
  34. Pentostatin for the treatment of chronic graft-versus-host disease in children.
    J Pediatr Hematol Oncol. 2003 Jul;25(7):584-8 PMID: 12847332
  35. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
    Biol Blood Marrow Transplant. 2003 Jul;9(7):417-25 PMID: 12869955
  36. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.
    Blood. 2003 Aug 1;102(3):814-9 PMID: 12689936
  37. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Bone Marrow Transplant. 2003 Aug;32(4):363-9 PMID: 12900772
  38. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody.
    Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11 PMID: 12931119
  39. Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Br J Haematol. 2003 Sep;122(5):778-87 PMID: 12930389
  40. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Nat Med. 2003 Sep;9(9):1144-50 PMID: 12925844
  41. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling.
    Br J Haematol. 2003 Nov;123(4):671-5 PMID: 14616971
  42. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.
    N Engl J Med. 2003 Dec 4;349(23):2201-10 PMID: 14657427
  43. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants.
    Blood. 2004 Jan 1;103(1):347-52 PMID: 12969970
  44. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
    Blood. 2004 Jan 1;103(1):353-9 PMID: 14512314
  45. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation.
    Transplantation. 2003 Dec 27;76(12):1742-9 PMID: 14688526
  46. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.
    Blood. 2004 Feb 15;103(4):1521-6 PMID: 14504099
  47. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
    Br J Haematol. 2001 Mar;112(3):820-3 PMID: 11260089
  48. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells.
    Blood. 2004 Mar 15;103(6):2410-6 PMID: 14604970
  49. Chronic graft-versus-host disease: where do we go from here?
    Bone Marrow Transplant. 2004 Mar;33(6):569-77 PMID: 14743199
  50. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines.
    Blood. 2004 Apr 15;103(8):3117-21 PMID: 15070693
  51. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children.
    Transplantation. 2004 Apr 15;77(7):1096-100 PMID: 15087778
  52. Transplantation tolerance induced by intranasal administration of HY peptides.
    Blood. 2004 May 15;103(10):3951-9 PMID: 14726386
  53. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.
    Blood. 2004 May 15;103(10):3986-8 PMID: 14764530
  54. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.
    Blood. 2004 Jun 1;103(11):4216-21 PMID: 14976053
  55. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease.
    Blood. 2004 Sep 1;104(5):1565-73 PMID: 15150080
  56. Association of Foxp3 regulatory gene expression with graft-versus-host disease.
    Blood. 2004 Oct 1;104(7):2187-93 PMID: 15172973
  57. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock.
    J Clin Immunol. 1995 Sep;15(5):266-73 PMID: 8537471
  58. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease.
    Am J Hematol. 1996 Jun;52(2):82-9 PMID: 8638646
  59. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.
    Br J Dermatol. 1996 May;134(5):848-54 PMID: 8736324
  60. Cytokine expression in human cutaneous chronic graft-versus-host disease.
    Bone Marrow Transplant. 1996 Jun;17(6):1085-92 PMID: 8807119
  61. Solid cancers after bone marrow transplantation.
    N Engl J Med. 1997 Mar 27;336(13):897-904 PMID: 9070469
  62. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Biol Blood Marrow Transplant. 1996 May;2(2):86-92 PMID: 9118303
  63. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Bone Marrow Transplant. 1997 Apr;19(7):691-5 PMID: 9156246
  64. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
    Blood. 1997 May 15;89(10):3880-7 PMID: 9160697
  65. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.
    Bone Marrow Transplant. 1997 Sep;20(5):365-8 PMID: 9339750
  66. Cutaneous graft-versus-host disease.
    Arch Dermatol. 1998 May;134(5):602-12 PMID: 9606330
  67. The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation.
    Bone Marrow Transplant. 1998 Jul;22(2):139-46 PMID: 9707021
  68. Autoimmune diseases and autoimmunity post-bone marrow transplantation.
    Bone Marrow Transplant. 1998 Nov;22(9):873-81 PMID: 9827815
  69. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    J Immunol. 1999 Nov 15;163(10):5693-9 PMID: 10553100
  70. Blockade of CTLA-4 signals inhibits Th2-mediated murine chronic graft-versus-host disease by an enhanced expansion of regulatory CD8+ T cells.
    J Immunol. 2000 Jan 15;164(2):664-9 PMID: 10623808
  71. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model.
    Blood. 2000 Jun 1;95(11):3613-9 PMID: 10828052
  72. IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice.
    J Immunol. 2001 Jan 1;166(1):170-81 PMID: 11123290
  73. How I treat chronic graft-versus-host disease.
    Blood. 2001 Mar 1;97(5):1196-201 PMID: 11222360
  74. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation.
    Blood. 2001 Mar 1;97(5):1458-66 PMID: 11222394
  75. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2000 Dec;26(12):1317-23 PMID: 11223972
  76. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.
    Blood. 2001 May 15;97(10):2948-56 PMID: 11342416
  77. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.
    J Clin Oncol. 2001 Aug 15;19(16):3685-91 PMID: 11504750
  78. Regulatory T cells in the control of immune pathology.
    Nat Immunol. 2001 Sep;2(9):816-22 PMID: 11526392
  79. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Transplantation. 2001 Aug 27;72(4):699-706 PMID: 11544434
  80. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation.
    Br J Haematol. 2001 Sep;114(4):931-6 PMID: 11564088
  81. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.
    J Immunol. 2001 Nov 1;167(9):4981-6 PMID: 11673505
  82. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.
    Blood. 2001 Nov 15;98(10):3162-4 PMID: 11698307
  83. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.
    Blood. 2001 Dec 1;98(12):3221-7 PMID: 11719357
  84. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
    Blood. 2002 Aug 15;100(4):1192-200 PMID: 12149197
  85. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.
    J Exp Med. 2002 Aug 5;196(3):389-99 PMID: 12163567
  86. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
    Blood. 2002 Sep 1;100(5):1611-8 PMID: 12176879
  87. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.
    Blood. 2004 Oct 15;104(8):2603-6 PMID: 15251978
  88. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton.
    Am J Pathol. 1976 Mar;82(3):493-512 PMID: 176891
  89. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.
    Am J Med. 1980 Aug;69(2):204-17 PMID: 6996481
  90. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
    Blood. 1981 Feb;57(2):267-76 PMID: 7004534
  91. An analysis of factors predisposing to chronic graft-versus-host disease.
    Exp Hematol. 1985 Nov;13(10):1062-7 PMID: 2996920
  92. Chronic graft-versus-host disease.
    Bone Marrow Transplant. 1990 Feb;5(2):69-82 PMID: 2178709
  93. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Blood. 1990 Jul 1;76(1):228-34 PMID: 2194590
  94. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver.
    Ann Intern Med. 1992 Apr 15;116(8):624-9 PMID: 1546861
  95. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice.
    Genes Dev. 1992 Aug;6(8):1444-56 PMID: 1379563
  96. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease.
    Infect Immun. 1995 Jun;63(6):2109-12 PMID: 7768588
  97. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease.
    Transplantation. 1999 Jan 15;67(1):59-65 PMID: 9921796
  98. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count.
    Bone Marrow Transplant. 1999 Apr;23(8):783-8 PMID: 10231140
  99. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    N Engl J Med. 1999 Jul 1;341(1):14-21 PMID: 10387937
  100. Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
    Science. 1999 Jul 16;285(5426):412-5 PMID: 10411505
  101. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.
    Biol Blood Marrow Transplant. 2005 Jan;11(1):47-55 PMID: 15625544
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
DOI
10.1182/blood-2004-10-4023
Email
stephanie_lee@dfci.harvard.edu
Published
2005-06-01
Epub
2005-00-08
Pages
4200-6
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC1895039
Subset
IM
Grants
NHLBI NIH HHS · P01 HL070149 · United States
External Links
PubMed source DOI: 10.1182/blood-2004-10-4023 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2